ArticleAnnals of medicine2023
Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.European journal of nuclear medicine and molecular imaging · 2026Trial
- Article
- Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.Cancer medicine · 2026Article
- Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease.Journal of translational medicine · 2026Article
- Exploring the applicability, combined strategies, and challenges of ablation in hematology based on its characteristics and immunomodulatory mechanisms.Clinical and experimental medicine · 2026Review
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Correlation between serum lactate dehydrogenase, βPakistan journal of medical sciences · 2026Article
- Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.HemaSphere · 2026Article
- Aggressive Extramedullary Multiple Myeloma Presenting as Small Bowel Obstruction.Journal of hematology · 2025Article
- Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).Mediterranean journal of hematology and infectious diseases · 2025Review
- Modified Glasgow Prognostic Score Incorporating CRP/Albumin Ratio and LDH Levels as Prognostic Indicators in Patients with Multiple Myeloma: A Retrospective Study.Cancer management and research · 2025Article
- Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.Frontiers in oncology · 2025Article
- The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.BMC cancer · 2024Article
- Transplant in myeloma: who, when, and why?Hematology. American Society of Hematology. Education Program · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.